Berlin – BioNTech has initiated a new legal battle against Moderna, alleging patent infringement related to its COVID-19 vaccine, mNexspike. This move escalates an ongoing dispute between the two pharmaceutical giants over intellectual property rights concerning the groundbreaking mRNA technology that underpinned some of the most widely used vaccines during the pandemic. The lawsuit, filed in Delaware federal court on Thursday, February 19, 2026, centers on claims that Moderna’s vaccine infringes upon patents held by BioNTech and its partner, Pfizer.
The core of the dispute revolves around the technology used to deliver messenger RNA (mRNA) into cells, prompting an immune response. Both the Pfizer-BioNTech Comirnaty vaccine and the Moderna Spikevax vaccine utilize this innovative mRNA technology, which instructs cells to produce a harmless spike protein, triggering the body’s defenses. However, BioNTech contends that Moderna’s vaccine unlawfully incorporates elements protected by its patents. This legal action follows a previous lawsuit filed by Moderna in 2022, alleging that Pfizer and BioNTech’s Comirnaty vaccine infringed upon Moderna’s patents. That case remains ongoing, signaling a broader trend of biotech companies seeking licensing fees for technologies employed in highly profitable COVID-19 vaccines.
The Expanding Legal Landscape of mRNA Vaccine Patents
The current legal clash between BioNTech and Moderna is not an isolated incident. It’s part of a larger pattern of patent disputes within the pharmaceutical industry, particularly concerning the rapidly developed COVID-19 vaccines. The immense financial success of these vaccines – generating billions in revenue for both companies – has intensified the focus on intellectual property protection. The stakes are high, as the outcome of these lawsuits could significantly impact future licensing agreements and the development of mRNA-based therapies beyond COVID-19.
While spokespersons for Moderna, BioNTech, and Pfizer initially declined to comment on the new lawsuit, the legal proceedings are expected to draw significant attention from the biotech sector and legal experts. The case will likely delve into the complexities of mRNA vaccine technology and the scope of patent protection for these innovations. Understanding the nuances of these patents is crucial, as they cover not only the mRNA sequence itself but as well the delivery systems and manufacturing processes involved.
mRNA Technology: A Revolution in Vaccine Development
The development of mRNA vaccines represents a significant breakthrough in medical science. Unlike traditional vaccines that use weakened or inactivated pathogens, mRNA vaccines utilize genetic instructions to trigger an immune response. This approach offers several advantages, including faster development times and greater adaptability to emerging viral variants. As MedNewsPedia explains, both Pfizer-BioNTech and Moderna vaccines share a similar mechanism, but differ in dosage and storage requirements.
The speed with which these vaccines were developed and deployed during the COVID-19 pandemic was unprecedented. The initial Phase 3 clinical data for Moderna’s vaccine in December 2020 mirrored the approximately 95% efficacy reported by Pfizer-BioNTech, demonstrating the potential of mRNA technology to rapidly address public health emergencies. However, data has also shown that protection from the initial two-dose mRNA vaccine series wanes over time, necessitating booster doses to maintain robust immunity, as noted by Yale Medicine. Yale Medicine highlights the importance of updated vaccines to combat evolving variants.
The Previous Moderna Lawsuit and Ongoing Disputes
The current lawsuit filed by BioNTech is a response, in part, to a legal action initiated by Moderna in 2022. Moderna alleged that Pfizer and BioNTech’s Comirnaty vaccine infringed upon its patents related to mRNA technology. This earlier case remains unresolved, adding another layer of complexity to the ongoing intellectual property battle. The legal arguments in both cases center on the specific components of the vaccines and whether they fall within the scope of the patents held by each company.
The broader implications of these disputes extend beyond the immediate financial interests of BioNTech and Moderna. They could shape the future of vaccine development and access, potentially influencing the cost and availability of mRNA-based therapies for other diseases. The outcome of these cases could also set precedents for how intellectual property rights are protected and enforced in the rapidly evolving field of biotechnology.
Comirnaty and Spikevax: A Comparative Overview
Both the Pfizer-BioNTech Comirnaty vaccine and the Moderna Spikevax vaccine have played a critical role in combating the COVID-19 pandemic. Both received Emergency Use Authorization from the FDA in December 2020 and have since been updated annually to target new virus variants. The Pfizer-BioNTech vaccine received full FDA approval in August 2021 for individuals aged 16 and older. While both vaccines are highly effective, subtle differences exist in their composition, dosage, and storage requirements.
The ongoing evolution of the SARS-CoV-2 virus and the emergence of new variants underscore the importance of continued vaccine development and adaptation. As of May 2025, the COVID-19 pandemic is in its sixth year, with Omicron subvariants continuing to drive infections in the United States. Despite the emergence of new variants, updated vaccines remain effective at preventing severe disease, hospitalization, and death, according to public health officials.
What Happens Next?
The legal proceedings initiated by BioNTech against Moderna are expected to unfold over the coming months. The initial phase will likely involve discovery, where both sides gather evidence to support their claims. This will be followed by potential motions, pre-trial hearings, and a trial if the case is not settled out of court. The timeline for a resolution remains uncertain, but the outcome could have significant ramifications for the future of mRNA vaccine technology and the pharmaceutical industry.
The Johnson & Johnson (Janssen) COVID-19 vaccine is no longer available in the U.S. As of May 6, 2023, and individuals who received it are considered up-to-date with their vaccinations when they follow current recommendations for updated vaccines. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) continue to provide updated guidance on COVID-19 vaccination and prevention strategies.
As this legal battle unfolds, it’s crucial to remember the vital role these vaccines have played in protecting public health. The development and deployment of mRNA vaccines represent a remarkable scientific achievement, and ongoing innovation is essential to address the evolving challenges posed by the virus.
Key Takeaways
- BioNTech has sued Moderna for patent infringement related to its COVID-19 vaccine, mNexspike.
- This lawsuit is part of a larger dispute between the two companies over intellectual property rights concerning mRNA technology.
- Moderna previously sued Pfizer and BioNTech in 2022, alleging patent infringement by Comirnaty; that case is ongoing.
- The outcome of these legal battles could significantly impact the future of mRNA vaccine development and access.
The next step in this legal process will be the court’s scheduling of initial hearings and the exchange of information between the two parties. We will continue to monitor this case and provide updates as they become available. Share your thoughts on this developing story in the comments below, and please share this article with your network.
Related reading